MannKind (MNKD) Shares Plunge on FDA Approval

Shares of MannKind Corp. (MNKD) plunged by as much as 20% at one point during Friday’s trading session after the US Food and Drug Administration [FDA] said the company’s newly approved inhalable diabetes drug “Afrezza” isn’t a substitute for long-term insulin use and must be used with long-acting insulin in patients with type 1 diabetes. […] View the full post at: MannKind (MNKD) Shares Plunge on FDA Approval Related posts: After-Hours Earnings (Feb. 1) Warren Buffett’s Holding Company Reduces Stake in Moody’s Shares HGSI’s Lupus Drug Shows Great Potential